<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20070130111707+01'00'</creation_date><modification_date>D:20070130111707+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-290_h_dec_2.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 26-i-2007 c(2007)311 
 not for publication</p></section><section><header>commission decision of 26-i-2007 
 amending the marketing authorisation for &quot;alimta - pemetrexed&quot;, a medicinal 
 product for human use, granted by decision c(2004)3580</header><p>(only the dutch text is authentic)</p></section><section><header>en  
   en</header></section><section><header>commission decision of 26-i-2007 
 amending the marketing authorisation for &quot;alimta - pemetrexed&quot;, a medicinal 
 product for human use, granted by decision c(2004)3580 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation for medicinal 
 products for human use and veterinary medicinal products falling within the scope of 
 council regulation (eec) no 2309/93
 2, and in particular the first subparagraph of article 6(10) thereof, 
 having regard to the application(s) submitted by eli lilly nederland b.v. on 15 october 
 2006 under article 6(1) of commission regulation (ec) no 1085/2003, 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 14 december 2006, 
 whereas: 
 (1)</p><p>an examination of the major variation type ii to the terms of the marketing 
 authorisation for the medicinal product &quot;alimta - pemetrexed&quot;, which is entered 
 in the community register of medicinal products under number(s) 
 eu/1/04/290/001 and the placing on the market of which was authorised by 
 decision c(2004)3580 of 20 september 2004, has shown that the product remains 
 in compliance with the requirements set out in directive 2001/83/ec of the 
 european parliament and of the council of 6 november 2001 on the community 
 code relating to medicinal products for human use
 3. (2)</p><p>it is therefore appropriate to accept the application(s) in respect of (a) major 
 variation(s) to the terms of the marketing authorisation and to amend decision 
 c(2004)3580 accordingly.</p><p>
 1 oj l 136, 30.4.2004, p. 1 2 oj l 159, 27.6.2003, p. 24. 3 oj l 311, 28.11.2001, p. 67. directive as last amended by directive 2004/27/ec (oj l 136, 30.4.2004, p.34).</p></section><section><header>en  
   en</header><p>has adopted this decision: article 1 decision c(2004)3580 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision; 
 2) annex ii is replaced by the text set out in annex ii to this decision; 
 3) annex iii is replaced by the text set out in annex iii to this decision. 
 article 2 this decision is addressed to eli lilly nederland b.v., grootslag 1-5, 3991 ra houten, nederland. 
 done at brussels, 26-i-2007 
 for the commission heinz zourek 
 director-general</p></section></body></xml>